Under the Paperwork Reduction Act of 1995, no persons are required to

Approved for use through 10/31/2002. OMB 065	
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMM	
respond to a collection of information unless it contains a valid OMB control	number

ubstitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE Application Number 09/932,538 April 16, 2003 August 17, 2001 STATEMENT BY APPLICANT First Named Inventor Bell, et al. Group Art Unit 1645 (use as many sheets as necessary) Examiner Name

Sheet	1	of	1		Attorne	y Docket	Number	37070	/205236	
				U.S. P	ATENT D	OCUME	NTS			
Examine r Initials *	Cite No.1	Number - Kind known)	nt Number 1 Code ² (if		ation Date DD-YYYY		Patentee or App Cited Document		Pages, Columns, Lines, Wi Passagas or Rele Figures Appes	vent
				ļ						
		<u> </u>		FOR	FIGN PAT	ENT DO	CUMENT			
Examiner Initials*	Cite No.1		n Patent Docur	nent	Publicatio MM-DD-	n Date	Name of P Applicant Docu	atentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7⁵
		-								·
		 								
		ļ								· · · · · · · · · · · · · · · · · · ·
		OTHE	D DDIOD A	PT NO	N DATEN	TIITE	RATURE D	OCUME	NTS	
Examiner	Cite No.1	Include na	me of the au	ithor (in C	APITAL LE	TTERS), mposium	title of the ar	ticle (whe	en appropriate), title of page(s), volume-issue	
RZ-		He, et al., "Calcium Phosphate Nanoparticle Adjuvant," Clinical and Diagnostic Laboratory Immunology, pp. 899-903 (November 2000)								
RZ		Protection	Against H	n Phosphate Nanoparticles Induce Mucosal Immunity and Herpes Simplex Virus Type 2," Clinical and Diagnostic blogy, pp. 1021-1024 (September 2002)						
	-									
		<u></u>	· —	<u></u>				<u> </u>	,	
				,						
Examine Signature		Coh &	Len	nen		Date Consid	ered	3/2	5/04	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use several s	sheets if necessary)		st 17, 2001	164	45	
		U.S. PATE	NT DOCUMENTS			
Examiner Initial	Document Number	Date	Name	Class	Subclass	Translation
P2	3,925,545	12/09/75	Relyveld	ı	<u> </u>	
RZ	4,016,252	04/05/97	Relyveld			
PŽ	4,350,686	09/21/82	Relyveld, et al.			
RZ	4,500,512	02/19/85	Barme			
PZ	4,552,756	11/12/85	Relyveld, et al.		,	
27	4,963,526	10/16/90	Ecanow			
RZ	5,110,606	05/05/92	Geyer, et. al			
RZ	5,178,882	01/12/93	Kossovsky et al.	·		
RX	5,219,577	06/15/93	Kossovsky et al.			
RZ	5,306,508	04/26/94	Kossovsky et al.			
er	5,334,394	08/02/94	Kossovsky et al.			
PZ	5,364,838	11/15/94	Rubsamen			
RZ	5,428,066	06/27/95	Larner, et al.			
RZ	5,460,830	10/24/95	Kossovsky et al.			
RZ	5,460,831	10/24/95	Kossovsky et al.			
PZ	5,462,750	10/31/95	Kossovsky et al.			
PZ	5,462,751	10/31/95	Kossovsky et al.			
RZ	5,464,634	11/07/95	Kossovsky et al.			
27	5,506,203	04/09/96	Backstrom et al.			
R2	5,549,973	08/27/96	Majetich et al.			
Pt	5,580,859	12/03/96	Felgner et al.			
85	5,593,875	01/14/97	Wurm, et al.			
RE	5,595,762	1/21/97	Derrieu et al.			
er	5,618,800	04/08/97	Kabra, et al.			
ez	5,620,896	04/15/97	Herrmann et al.			
RE	5,629,021	05/13/97	Wright			
RZ	5,641,515	06/24/97	Ramtoola			
RX	5,648,097	7/15/97	Nuwayser			
RZ	5,665,382	09/09/97	Grinstaff, et al.			
22	5,695,617	12/09/97	Gravier et al.			
RZ	5,747,001	05/05/98	Wiedmann et al.			
R2	5,785,975	07/28/98	Parikh			
RE	5,824,638	10/20/98	Burnside, et al.			
RŽ	5,827,822	10/27/98	Floc'h et al.			
PŽ	5,843,887	12/01/98	Petit, et al.			
RZ	5,858,398	01/12/99	Cho			
RE	5,866,553	02/02/99	Donnelly et al.			
RX	5,891,420	04/06/99	Cutie			
22	5,898,028	04/27/99	Jensen et al.		,	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Application No. Docket No.: 09/932,538 37070/205236 orm PTO-1449 Applicant: INFORMATION DISCLOSURE Bell et al. CITATION Group Art Unit Filing Date: IN AN APPLICATION 1645 August 17, 2001 (Use several sheets if necessary) 05/11/99 Stolz · 5,902,789 12 Jacob, et al. 11/16/99 5,985,312 px 01/25/00 Modi RZ 6,017,545 2/05/00 Santos, et al. · 6,156,348 Morcoletal 02/06/01 6,183,803 02/13/01 Brey, et al. 6,187,335 03/12/02 Bell, et al. 6,355,271 NON US PATENTIDOCUMENTS Subclass Translation Country **Document Number** Examiner Initial 10/04/90 W WO 90/I 1092 RZ WO 93/17706 09/16/93 12/09/93 WO 93/24640 ρł WO98/35562 08/20/98 RZ 03/23/00 WO00/15194 UK 22 1422973 abstract France 7212036* 12/07/73 abstract 7924948** 04/17/81 France **PCT** WO 00/46147 08/10/00 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Abstracts of Papers Presented at the 1992 meeting on Modern Approaches to New Vaccines, Including Prevention of AIDS, Cold Spring Harbor), Vaccine 11: 92 (1993). RZ Abu-Izza, K.A, "Effect of gastrointestinal protein adsorption on the in vitro release of AZT RX from ethylcellulose microspheres," Pharm. Dev. Technol., 3(4):49-501 (1998). (abstract) Al-Achi, et al., "Erythrocytes as Oral Delivery Systems for Human Insulin," Drug QX Development and Industrial Pharmacy, 24(1):67-72 (1998) Aldovini and R. A. Young, "Humoral and cell-mediated immune responses to live lΧ recombinant BCG-HIV vaccines," Nature 351: 479-482 (1991). Ascadi et al., "Human dystrophin expression in mdx mice after intramuscular injection of W DNA constructs," Nature 352: 815-818 (1991). Bartus et al., "Sustained Delivery of Proteins for Novel Therapeutic Products," Science, W 281(5380): 1161-1162 (1998). Bastin, et al., "Use of Synthetic Peptides of Influenza Nucleoprotein to Define Epitopes Recognized by Class I-Restricted Cytotoxic T Lymphocytes," J. Exp. Med., 165(4): 1508fix 1523 (1987). Bayomi, M.A., "Preparation of casein-chitosan microspheres containing diltiazem hydrochloride by an aqueous coacervation technique," Pharma. Acta. Helv., 73(4):187-92 R (1998), (abstract) Date Considered Examiner: EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Sheet 3 of 6

Application No. Docket No.: Form PTO-1449 09/932.538 37070/205236 Applicant: INFORMATION DISCLOSURE Bell et al. CITATION Filing Date: Group Art Unit IN AN APPLICATION (Use several sheets if necessary) 1645 August 17, 2001 Benvenisty, N., and Reshef, L. "Direct introduction of genes into rats and expression of genes," PNAS 83, 9551-9555, (1986) Bennink and J. W. Yewdell, "Recombinant Vaccinia Viruses as Vectors for Studying T RR Lymphocyte Specificity and Function," Curr. Top. Microbiol. Immunol., 163: 153-184 (1990) Bulgarelli, et al., "Effect of matrix composition and process conditions on casein-gelatin RZ beads floating properties, "Int. J. Pharm., 198(2):157-65 (2000). (abstract) Bulgarelli, et al., "Casein/gelatin beads: I. Cross-linker solution composition effect on cross-RX linking degree," Int. J. Pharm., 190(2):175-182 (1999). (abstract) Carbone and Bevan, "Induction of Ovalbumin-specific cytotoxic T cells by in vivo peptide lz. immunization," J. Exp. Med., 169(1): 603-612 (1989). Chen, et al., Comparison of albumin and casein microspheres as a carrier for doxorubicin, 27 J. PHARM. PHARMACOL., 39(12):978-85 (1987) Choudhari, et al., Liposomes As a Carrier for Oral Administration of Insulin: Effect of RZ Formulation Factors, 11 (3) JOURNAL OF MICROENCAPSULATION, 319-325 (1994) Collins et al., "Processing of exogenous liposome-encapsulated antigens in vivo generates RZ class I MCH-restricted T cell responses," J. Immunol., 148(11): 3336-3341 (1992). Cooney et al., "Safety of and immunological response to a recombinant vaccinia virus vaccine 27 expressing HIV envelope glycoprotein," Lancet, 337: 567-572 (1991). Cox et al., "Bovine Herpesvirus 1: Immune Responses in Mice and Cattle Injected with RZ Plasmid DNA," 1993, J. Virol., 67(9): 5664-5667. Damge, et al., "New approach for Oral Administration Insulin With Polyalkylcyanoacrylate R2 Nanocapsules as Drug Carrier," *Diabetes*, 37:246-251 (1988) Damge, et al., "Poly(alkyl cyanoacrylate) Nanospheres for Oral Administration of Insulin," RZ J.Pharm. Sci., 86(12):1403-1409 (1997) Deres, et al., "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic fZ. lipoprotein vaccine," Nature, 342: 561-564 (1989). Donnelly et al., "DNA Vaccines," Annu. Rev. Immunol., 15: 617-648 (1997). Edgington, "Turning On Tumor-Fighting T-Cells," Biotechnology, 11:1117-1119 (1993). Edwards et al., "Large Porous Particles for Pulmonary Drug Delivery," Science, 276:1868-1871 (1997). Friedman, T., "Progress toward human gene therapy," Science, 244, 1275-1281 (1989). ex Furth et al., "Gene Transfer into Somatic Tissues by Jet Injection," Analytical Biochemistry, RZ 205(2): 365-368, (1992). Gardner et al., "Cell-mediated cytotoxicity against ectromelia virus-infected target cells," Eur. RX J. Immunol., 4: 68-72 (1974). Goto et al., "Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminum hydroxide with different physical properties," Vaccine, 15(12/13):1364-1371 દર (1997).Hahn et al., "Infectious Sindbis virus transient expression vectors for studying antigen RX processing and presentation," Proc. Natl. Acad. Sci. (USA) 89: 2679-2683 (1992). Hansen et al., "Strong Expression of Foreign Genes Following Direct Injection into Fish RZ Muscle," FEBS Lett. 290, 73-76 (1991). Date Considered: 3/25/04 Examiner: EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Application No. Docket No.: 09/932,538 orm PTO-1449 37070/205236 Applicant: INFORMATION DISCLOSURE Bell et al. CITATION Group Art Unit IN AN APPLICATION Filing Date: (Use several sheets if necessary) August 17, 2001 1645 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Heelan, et al., "In vitro analysis of the release of incorporated agents from sodium caseinate RX microspheres," J. Microencapsul., 14(1):63-78 (1997). (abstract) Hosny, et al, "Promotion of oral insulin adsorption in diabetic rabbits using pH-dependent coated capsules containing sodium cholate," Pharm. Acta. Helv., 72(4):203-7 (1997). RX Hosny, "Hypoglycemic Effect Of Oral Insulin in Diabetic Rabbits Using pH-Dependent Coated Capsules Containing Sodium Salicylate Without And With Sodium Cholate," 24(3) LK. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY 24(3):307-311 (1998) Kato et al., "Relationship between Hemolytic Activity and Adsorption Capacity of Aluminum Hydroxide and Calcium Phosphate as Immunological Adjuvants for Biologicals," Microbiol. LZ Immunol., 38(7): 543-548 (1994). Kimura, et al., Oral Administration of Insulin as Poly(Vinyl Alcohol)-Gel Spheres in Diabetic RX Rats, 19(6) BIOL. PHARM. BULLETIN, 19(6):897-900 (1996). (abstract) Kitsis et al., "Hormonal modulation of a gene injected into rat heart in vivo," Proc. Natl. RZ Acad. Sci. (USA) 88: 4138-4142 (1991). Knepp, "Synthesis, properties, and intratumoral evaluation of mitoxantrone-loaded casein microspheres in Lewis lung cacimnoma, "45(10) J. PHARM. PHARMACOL, 887-91 (1993). RZ (abstract) Latha, "Progesterone release from glutaraldehyde cross-linked casein microspheres: in vitro eł studies and in vivo response in rabbits, "61(5) CONTRACEPTION, 329-34 (2000). (abstract) Latha, "Glutaraldehyde cross-linked bovine casein microspheres as a matrix for the controlled release of theophylline: in0vitro studie," 46(1) J. PHARM. PHARMACOL, 8-13 (1994). 22 Latha, et al., "Casein as a carrier matrix for 5- fluorouracil: drug release from microspheres, drug-protein conjugates and in-vivo degradation microspheres in rat muscle," 46(11) J. RZ PHARM. PHARMACOL, 858-62 (1994) Latha, et al., "A new method for the synthesis of smooth, round, hydrophilic protein microspheres using low concentrations of polymeric dispersing agents," J. Microencapsl., RX 12(1):7-12 (1995). (abstract) Lin et al., "Expression of Recombinant Genes in Myocardium In Vivo after Direct Injection RZ of DNA," Circulation 82(6): 2217-2221 (1990). Lin and Askonas, "Biological properties of an influenza A virus-specific killer T cell clone," RZ J. Exp. Med. 154(1): 225-234 (1981). Lowman, "Oral Delivery of Insulin Using pH-Responsive Complexation Gels," 88(9) RZ JOURNAL OF PHARMACEUTICAL SCIENCES, 933-937 (1999) Maniatis, et al., "Molecular Cloning, A laboratory Manuel, 2nd Edition," Cold Spring Harbor a Laboratory Press, New York, 1.0 - 19.0 (1989). * Mascola et al., "Surveillance of Listeriosis in Los Angeles County, 1985-1986," Arch. Intern. RX Med., 149(7): 1569-1572 (1989). McMichael et al., "Cytotoxic T-Cell Immunity to Influenza," New Engl. J. Med., 309(1): 13-17 (1983) Date Considered: Examiner EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

r-3/	Docket No.:		Application No.			
50rm PTO-1449	37070	0/205236	09/932,538			
INFORMATION DISCLO		Applicant: Bell et al.				
IN AN APPLICATION (Use several sheets if new	ON Filing Date: cessary) Augu:	st 17, 2001	Group Art Unit 1645			
OTH	ER DOCUMENTS (Includia	ng Author, Title, Date, Pertinen	t Pages, Etc.)			
Mo	Michael et al., "Recognition aphocytes," J. Gen. Virol., 67	l., "Recognition of Influenza A virus Nucleoprotein by human cytotoxic T				
Mi Ab	Michel, et al., "The Effect of Site of Administration in the Gastrointestinal Tract on the Absorption of Insulin from Nanocapsules in Diabetic Rats," J. Pharm. Pharmacol., 43:1-5 (1991)					
R7 Mi	ller, "Retroviral Vectors," Ci	urr. Top. Microbiol. Immunol	¹ .,158, 3-24 (1992).			
LZ Mu sus EN	Miller, "Retroviral Vectors," Curr. Top. Microbiol. Immunol., 158, 3-24 (1992). Musabayane, et al., Orally administered, insulin-loaded amidated pectin hydogel beads sustain plasma concentrations of insulin in streptozotocin-diabetic rats, 164(1) JOURNAL OF ENDOCRINOLOGY, 1-6 (2000)					
RE mi	xed micelle systems, " Pharn	n. Res. 10(6):865-70 (193). (a	of hydrocortisone in simple and abstract)			
P2 Sec No Ac	Olivares, et al., Effects of a Protective Hydrolized Casein Diet Upon the Metabolic and Secretory Responses of Pancreatic Islets to IL-1\(\beta\), Cytokine Production by Mesenteric Lymph Node Cells, Mitogenic and Biosynthetic Activities and Peyers' Patch Cells, and Mitogenic Activity and Pancreatic Lymph Node Cells from Control and Diabetes-Prone BB Rats, 68(3) MOLECULAR GENETICS AND METABOLISM 379-390 (1999)					
Kゼ	Redfield et al., "Disseminated Vaccinia in a Military Recruit with Human Immunodeficiency Virus (HIV) Disease," New Engl. J. Med., 316(11): 673-676 (1987).					
had had	Robinson et al., "Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA," <i>Vaccine</i> 11(9): 957-960 (1993).					
Ro	Rowland, et al., "The stability of liposome's in vitro to pH, bile salts and pancreatic lipase," Biochem. Biophsy. Acta., 620(3):400-9 (1980)					
Sau Sau	Santinho, et al., Influence of formulation on the physiochemical properties of casein microparticles, 186(2) INTL. JOURNAL OF PHARMACEUTICS, 191-98 (1999)					
Sa	Sato et al., "Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization," Science 273: 352-354 (1996).					
RZ Sc.	Schafer et al., "Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine," J. Immunol., 149(1):53-59 (1992).					
RE Sto	Stover et al., "New use of BCG for recombinant vaccines," Nature 351: 456-460 (1991).					
R7 Ta	Takahashi et al., "Induction of CD8 cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs," <i>Nature</i> , 344: 873-875 (1990).					
RZ Ta	Tang et al., "Genetic immunization is a simple method for eliciting an immune response," Nature, 356: 152-154 (1992).					
Ta Ta	Taylor and Askonas "Influenza nucleoprotein-specific cytotoxic T-cell clones are protective					
Examiner: Date Considered: /						
1 Kind of	Lamon	3/25/04				
EXAMINER: Initial if citation not in conformance and not	considered, whether or not citat considered. Include copy of this	ion is in conformance with MPEF form with next communication to	§ 609; Draw line through citation if the applicant.			

APR 1 5 2002

		Docket No.:	Application No.						
Form PTO-1449		37070/205236	09/932,538						
:- Form P10-1449		Applicant:							
INFOR	RMATION DISCLOSURE	Bell et al.							
18	CITATION I AN APPLICATION	Filing Date:	Group Art Unit						
	veral sheets if necessary)	August 17, 2001	1645						
			d T lymphocytes," Annu. Rev. Immunol.,						
RE	7: 601-624 (19	- ·							
1-5	Townsend et al	"The Enitones of Infulenza Nucleo	protein Recognized by Cytotoxic T						
RZ	Lymphocytes (al., "The Epitopes of Infulenza Nucleoprotein Recognized by Cytotoxic T Can Be Defined with Short Synthetic Peptides," Cell 44: 959-968 (1986).							
PC	Tozaki et al. "	Tozak, et al., "Chitosan Capsules for Colon-Specific Drug Delivery: Improvement of Insulin							
RZ	Absorption from	n the Rat Colon," J. Pharm. Sci., 860	(9)·1016-1021 (1997)						
	Trool et al. "C	ral administration of insulin by mean	os of linosome's in animal experiments"						
RZ	(outhor's trans)	agl, et al., "Oral administration of insulin by means of liposome's in animal experiments" ithor's trans), Wine Klin Wochenschr, 91(13):448-51 (1979) Abstract only							
	Illmer I R et	al "Heterologous Protection Agains	t Influenza by Injection of DNA						
RZ		et al., "Heterologous Protection Against Influenza by Injection of DNA //iral Protein," Science, 259: 1745-1749 (1993).							
	Wang et al "C	ene inoculation generates immune re	esponses against human immunodeficiency						
PZ	wang et al., O	Wang et al., "Gene inoculation generates immune responses against human immunodeficiency							
	Wang et al. "I	virus type I," P.N.A.S. USA 90: 4156-4160 (May, 1993). Wang, et al., "Enhanced type I immune response to a hepatitis B DNA vaccine by formulation							
RZ	wang, et al., I	wang, et al., "Ennanced type I immune response to a nepatitis B DIVA vaccine by formulation with calcium- or aluminum phosphate," <i>Vaccine</i> , 18: 1227-1235 (2000).							
100	Weiner et al. "	Immunostimulatory oligodeoxynucle	entides containing the CnG motif are						
	offective as im	Weiner et al., "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization," PNAS (USA) 94(19): 10833-							
Ot									
	Willmott et al.	10837 (1997). Willmott, et al., "Biodegradation rate of embolized protein microspheres in lung, liver and							
RZ		J. Pharm. Pharmacol., 41(7):433-4							
	Willmost at al	Dovorubicin-loaded casein microsm	sheres: protein nature of drug						
· RZ		Willmott, et al., Doxorubicin-loaded casein microspheres: protein nature of drug incorporation, 44(6) J. PHARM. PHARACOL, 472-75 (1992)							
	Wolff et al. "I	ong term persistence of plasmid DN	A and foreign gene expression in mouse						
RZ									
muscle," Human Mol. Genet. 1(6): 363-369 (1992). Wolff et al., "Direct Gene Transfer into Mouse Muscle in Vivo," Science 247: 1465-1468									
RZ	(1990).								
Yap and Ada, "Transfer of specific cytotoxic T lymphocytes protects mice inoculated with									
influenza virus," Nature, 273: 238-239 (1978).									
Yewdell et al., "Influenza A virus nucleoprotein is a major target antigen for cross-reactive									
10	anti-influenza	anti-influenza A virus cytotoxic T lymphocytes," <i>Proc. Natl. Acad. Sci.</i> (USA) 82: 1785-1789							
anti-influenza A virus cytotoxic T lymphocytes," <i>Proc. Natl. Acad. Sci.</i> (USA) 82: 178. (1985).									
	Zhu et al "Sys	temic Gene Expression After Intrave	enous DNA Delivery into Adult Mice,"						
Rt		Science 261: 209-211 (1993).							
RX		http://vaxa.com/html/669.cfm							
<u>m</u>	intp:// vaxu.com	442.11							
<u> </u>									
Examiner: Date Considered: /									
Nohut temen 3/25/04									
EXAMINE	R: Initial if citation considered, v	whether or not citation is in conformance	with MPEP § 609; Draw line through citation if						
	amanaa and not considered. I	actude conv of this form with next commu	nication to the applicant.						